Chris Yu's questions to Vertex Pharmaceuticals Inc (VRTX) leadership • Q3 2024
Question
Chris Yu, on for Terence Flynn at Morgan Stanley, asked about the pricing strategy for suzetrigine, seeking insight into the key inputs Vertex is considering for its pricing decisions.
Answer
Chief Operating Officer Stuart Arbuckle stated that suzetrigine's price will be determined by the level of clinical benefit it provides and the significant unmet need it addresses for both individual patients and society. The final pricing decision will be made closer to the approval date.